Menter Thomas, Trivedi Pritesh, Ahmad Raida, Flora Rashpal, Dirnhofer Stephan, Tzankov Alexandar, Naresh Kikkeri N
From the Department of Cellular and Molecular Pathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, London, UK; and.
Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Am J Clin Pathol. 2017 Mar 1;147(3):292-300. doi: 10.1093/ajcp/aqw208.
Recent studies have shown that lymphoid enhancer binding factor 1 (LEF1) is a useful marker for chronic lymphocytic B-cell leukemia (CLL)/small lymphocytic lymphoma. Yet, it is not still being widely used in a diagnostic setting. In this study, we document the experience with LEF1 immunohistochemistry during routine diagnostics.
In total, 191 B-cell lymphoma cases from Hammersmith Hospital, Imperial College NHS Healthcare Trust (London, UK) were investigated by immunohistochemistry for LEF1 during routine diagnostic workup. These cases included both bone marrow trephines and lymph node biopsy specimens. The monoclonal antibody clone EPR2029Y was used.
LEF1 expression was strong and diffuse (>70% of cells) in most cases. Few CLL cases showed a staining in proliferation centers only. Seventy-seven of 80 CLL cases expressed LEF1. Other entities expressing LEF1 included one of 38 follicular lymphomas, two of 33 marginal zone lymphomas, and one diffuse large B-cell lymphoma with a background of follicular lymphoma grade 3B. Sensitivity for LEF1 for the diagnosis of CLL was 0.96, and specificity was 0.93.
In this study, we could demonstrate the diagnostic utility of LEF1. LEF1 is a sensitive and specific marker for CLL and is helpful in the diagnosis of diagnostically challenging small B-cell lymphomas.
近期研究表明，淋巴样增强因子1（LEF1）是慢性淋巴细胞性B细胞白血病（CLL）/小淋巴细胞淋巴瘤的一个有用标志物。然而，它在诊断环境中仍未得到广泛应用。在本研究中，我们记录了常规诊断过程中LEF1免疫组化的经验。
在常规诊断检查期间，对来自英国伦敦帝国学院国民保健服务信托基金哈默史密斯医院的191例B细胞淋巴瘤病例进行了LEF1免疫组化研究。这些病例包括骨髓切片和淋巴结活检标本。使用单克隆抗体克隆EPR2029Y。
在大多数病例中，LEF1表达强烈且弥漫（>70%的细胞）。少数CLL病例仅在增殖中心有染色。80例CLL病例中有77例表达LEF1。其他表达LEF1的实体包括38例滤泡性淋巴瘤中的1例、33例边缘区淋巴瘤中的2例以及1例伴有3B级滤泡性淋巴瘤背景的弥漫性大B细胞淋巴瘤。LEF1对CLL诊断的敏感性为0.96，特异性为0.93。
在本研究中，我们能够证明LEF1的诊断效用。LEF1是CLL的一个敏感且特异的标志物，有助于诊断具有挑战性 的小B细胞淋巴瘤。
